Highlights Tharimmune, Inc.

Equities

THAR

US4327052001

Real-time Estimate Cboe BZX Other stock markets 02:58:50 2024-05-15 pm EDT			5-day change	1st Jan Change
0.366 ^USD	+0.38%		-11.18%	-28.55%

May. 09	Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	Apr. 23	CI
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	Feb. 20	CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	Feb. 05	CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	Jan. 29	CI
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	Dec. 11	CI
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	Nov. 27	CI
Tharimmune to Implement 1-for-25 Reverse Stock Split	Nov. 17	MT
Tharimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Tharimmune, Inc. Announces Execution of an Exclusive Worldwide Licensing Agreement with Avior Inc. D/B/A Avior Bio, Llc ("Avior") to Develop, Market and Commercialize A Clinical-Stage Asset, Av104 (To Be Renamed Th104 and Hereinafter Referred to as Th104)	Nov. 06	CI
Hillstream BioPharma Changes Name to Tharimmune; Expects Closing of Clinical Stage Asset Acquisition in Q4	23-09-22	MT
Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset	23-09-22	CI
Tharimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Hillstream Expands Collaboration With Minotaur, License Deal With OmniAb to Develop Cancer Treatments; Shares Rise	23-07-20	MT
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics	23-07-10	CI
Hillstream Biopharma, Inc. Announces the Signing of an Exclusive Agreement with Applied Biomedical Science Institute	23-07-06	CI
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Hillstream BioPharma, Inc. Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data	23-04-10	CI
Banks Remain in Focus With Exchange-Traded Funds, Equity Futures Narrowly Mixed Premarket Monday	23-03-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tharimmune, Inc.

Equities

THAR

US4327052001

Highlights

Filters